Revvity Reports Strong Q1 2026 Earnings with Strategic Divestiture
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RVTY?
Source: seekingalpha
- Performance Growth: Revvity generated $711 million in revenue for Q1 2026, achieving a 3% year-over-year growth, with an adjusted operating margin of 23.6% exceeding expectations, indicating improved operational efficiency that is likely to enhance future profitability.
- Strategic Restructuring: The company plans to divest its immunodiagnostics business in China, which accounted for approximately 6% of total revenue last year, aiming to address persistent policy challenges, with the transaction expected to close within two years while retaining a minority stake in the new entity.
- Outlook Update: Management has revised its full-year 2026 targets, projecting organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, reflecting confidence in operational execution and adaptability to market changes.
- Cash Flow Performance: The company reported free cash flow of $115 million in Q1, resulting in a robust 97% conversion of adjusted net income into cash flow, demonstrating strong capital management, while the net debt to adjusted EBITDA leverage ratio stood at 2.8x, indicating a healthy financial position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 86.510
Low
105.00
Averages
113.38
High
123.00
Current: 86.510
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revvity Reports Strong Q1 2026 Earnings with Strategic Divestiture
- Performance Growth: Revvity generated $711 million in revenue for Q1 2026, achieving a 3% year-over-year growth, with an adjusted operating margin of 23.6% exceeding expectations, indicating improved operational efficiency that is likely to enhance future profitability.
- Strategic Restructuring: The company plans to divest its immunodiagnostics business in China, which accounted for approximately 6% of total revenue last year, aiming to address persistent policy challenges, with the transaction expected to close within two years while retaining a minority stake in the new entity.
- Outlook Update: Management has revised its full-year 2026 targets, projecting organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, reflecting confidence in operational execution and adaptability to market changes.
- Cash Flow Performance: The company reported free cash flow of $115 million in Q1, resulting in a robust 97% conversion of adjusted net income into cash flow, demonstrating strong capital management, while the net debt to adjusted EBITDA leverage ratio stood at 2.8x, indicating a healthy financial position.
See More
Revvity (RVTY) Q1 2026 Earnings Transcript
See More
Revity Executive States Company Intends to Maintain Caution with Future Projections - Conference Call
Company's Stance: Revvity executives emphasize the importance of maintaining a prudent approach in their forward-looking strategies.
Focus on Assumptions: The company is concentrating on the assumptions that will guide their future plans and decisions.
See More
Revvity to Host Q1 2026 Earnings Call on May 5, 2026
- Earnings Call Announcement: Revvity, Inc. will host a conference call on May 5, 2026, at 7:30 AM ET to discuss its Q1 2026 earnings results, which is expected to provide critical insights into the company's financial health.
- Webcast Access: Investors can participate in the call by accessing the event page on the company's website, ensuring they receive real-time financial information and enhancing engagement with stakeholders.
- Market Reaction Anticipation: This earnings call is likely to offer investors insights into Revvity's future performance, potentially impacting the market's perception of the company's stock, especially around the time of the financial data release.
- Transparency Enhancement: By conducting regular earnings calls, Revvity aims to improve information transparency and bolster investor confidence, which could contribute to the stability and growth of the company's stock price.
See More
Revvity Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Revvity reported a Q1 non-GAAP EPS of $1.06, beating expectations by $0.05, indicating ongoing improvements in profitability and boosting investor confidence.
- Robust Revenue Growth: The company achieved Q1 revenue of $711.12 million, reflecting a 7.0% year-over-year increase and surpassing analyst expectations by $7.06 million, demonstrating strong market competitiveness and product demand.
- 2026 Financial Guidance: Revvity forecasts total revenue for 2026 between $2.81 billion and $2.84 billion, below the consensus of $2.98 billion, indicating a cautious outlook on future growth, with pro forma organic revenue growth projected at 3%-4%.
- Adjusted EPS Expectations: The adjusted EPS forecast for 2026 is set at $5.20 to $5.30, lower than the consensus of $5.40, reflecting a conservative approach to earnings expectations that may impact short-term investor sentiment.
See More
Revvity Scheduled to Announce Q1 Earnings on May 5th
- Earnings Announcement: Revvity (RVTY) is set to release its Q1 2023 earnings on May 5th before market open, with consensus EPS estimated at $1.01 (flat YoY) and revenue expected at $704.06 million (+5.9% YoY), indicating resilience in stable growth.
- Historical Performance: Over the past two years, RVTY has exceeded EPS estimates 100% of the time and revenue estimates 75% of the time, showcasing strong performance in profitability and market expectation management.
- Estimate Revision Trends: In the last three months, EPS estimates have seen no upward revisions and 11 downward adjustments, reflecting cautious market sentiment regarding the company's earnings potential; however, revenue estimates have experienced 9 upward revisions, indicating ongoing confidence in revenue growth.
- Industry Conference Participation: Revvity has recently participated in several key industry conferences, including Barclays' 28th Annual Global Healthcare Conference and TD Cowen's 46th Annual Healthcare Conference, demonstrating the company's engagement in the industry and transparency with investors, which may help bolster market confidence.
See More
Revvity Reports Strong Q1 2026 Earnings with Strategic Divestiture
- Performance Growth: Revvity generated $711 million in revenue for Q1 2026, achieving a 3% year-over-year growth, with an adjusted operating margin of 23.6% exceeding expectations, indicating improved operational efficiency that is likely to enhance future profitability.
- Strategic Restructuring: The company plans to divest its immunodiagnostics business in China, which accounted for approximately 6% of total revenue last year, aiming to address persistent policy challenges, with the transaction expected to close within two years while retaining a minority stake in the new entity.
- Outlook Update: Management has revised its full-year 2026 targets, projecting organic growth of 3% to 4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20 to $5.30, reflecting confidence in operational execution and adaptability to market changes.
- Cash Flow Performance: The company reported free cash flow of $115 million in Q1, resulting in a robust 97% conversion of adjusted net income into cash flow, demonstrating strong capital management, while the net debt to adjusted EBITDA leverage ratio stood at 2.8x, indicating a healthy financial position.
See More
Revvity (RVTY) Q1 2026 Earnings Transcript
See More
Revity Executive States Company Intends to Maintain Caution with Future Projections - Conference Call
Company's Stance: Revvity executives emphasize the importance of maintaining a prudent approach in their forward-looking strategies.
Focus on Assumptions: The company is concentrating on the assumptions that will guide their future plans and decisions.
See More
Revvity to Host Q1 2026 Earnings Call on May 5, 2026
- Earnings Call Announcement: Revvity, Inc. will host a conference call on May 5, 2026, at 7:30 AM ET to discuss its Q1 2026 earnings results, which is expected to provide critical insights into the company's financial health.
- Webcast Access: Investors can participate in the call by accessing the event page on the company's website, ensuring they receive real-time financial information and enhancing engagement with stakeholders.
- Market Reaction Anticipation: This earnings call is likely to offer investors insights into Revvity's future performance, potentially impacting the market's perception of the company's stock, especially around the time of the financial data release.
- Transparency Enhancement: By conducting regular earnings calls, Revvity aims to improve information transparency and bolster investor confidence, which could contribute to the stability and growth of the company's stock price.
See More
Revvity Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Revvity reported a Q1 non-GAAP EPS of $1.06, beating expectations by $0.05, indicating ongoing improvements in profitability and boosting investor confidence.
- Robust Revenue Growth: The company achieved Q1 revenue of $711.12 million, reflecting a 7.0% year-over-year increase and surpassing analyst expectations by $7.06 million, demonstrating strong market competitiveness and product demand.
- 2026 Financial Guidance: Revvity forecasts total revenue for 2026 between $2.81 billion and $2.84 billion, below the consensus of $2.98 billion, indicating a cautious outlook on future growth, with pro forma organic revenue growth projected at 3%-4%.
- Adjusted EPS Expectations: The adjusted EPS forecast for 2026 is set at $5.20 to $5.30, lower than the consensus of $5.40, reflecting a conservative approach to earnings expectations that may impact short-term investor sentiment.
See More
Revvity Scheduled to Announce Q1 Earnings on May 5th
- Earnings Announcement: Revvity (RVTY) is set to release its Q1 2023 earnings on May 5th before market open, with consensus EPS estimated at $1.01 (flat YoY) and revenue expected at $704.06 million (+5.9% YoY), indicating resilience in stable growth.
- Historical Performance: Over the past two years, RVTY has exceeded EPS estimates 100% of the time and revenue estimates 75% of the time, showcasing strong performance in profitability and market expectation management.
- Estimate Revision Trends: In the last three months, EPS estimates have seen no upward revisions and 11 downward adjustments, reflecting cautious market sentiment regarding the company's earnings potential; however, revenue estimates have experienced 9 upward revisions, indicating ongoing confidence in revenue growth.
- Industry Conference Participation: Revvity has recently participated in several key industry conferences, including Barclays' 28th Annual Global Healthcare Conference and TD Cowen's 46th Annual Healthcare Conference, demonstrating the company's engagement in the industry and transparency with investors, which may help bolster market confidence.
See More
